Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05310838 · ClinicalTrials.gov registry record · NA
Optimizing Engagement in Services for First-Episode Psychosis
A NA study of First Episode Psychosis and Engagement, Patient, sponsored by California State University, San Bernardino.
- Active
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT05310838: Active NA study of First Episode Psychosis and Engagement, Patient, sponsored by California State University, San Bernardino.
NCT05310838 is a NA study of First Episode Psychosis and Engagement, Patient that is active but no longer recruiting, run by California State University, San Bernardino. The registered enrollment target is 58 participants, below the 6,426-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05310838, a NA study of First Episode Psychosis and Engagement, Patient, is active but no longer recruiting, sponsored by California State University, San Bernardino.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample of Latinos with FEP and their families. Comparable family group sessions will also be delivered to participants in both conditions. It is expected that BA participants will show better engagement than TAU participants.
Primary Outcome
PAM13 is a 13-item self-report short form of a patient's engagement in the care process at four stages. PAM13 shows high reliability that is stable across chronic illnesses and high construct validity, and measures change over time. Items are rated on a 4-point Likert scale (totally disagree to totally agree) with higher scores reflecting higher activation; respondent may select 'not applicable.'
Conditions Studied
Interventions
- BEHAVIORAL Treatment As Usual
- BEHAVIORAL Behavioral Activation for First Episode Psychosis
Study Locations (2)
California
- San Fernando Mental Health Center - Granada Hills
- Olive View - UCLA Medical Center - Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05310838 still lists
NCT05310838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 6,426-participant average among 8 other First Episode Psychosis trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with First Episode Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Treatment As Usual is the first listed.
NCT05310838 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05310838 about?
NCT05310838 is a clinical study titled "Optimizing Engagement in Services for First-Episode Psychosis". This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample of Latinos with FEP and their families. Comparable family group sessions...
What is the current status of trial NCT05310838?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 58 participants. The study started on 2022-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05310838 study?
This clinical trial studies the following conditions: First Episode Psychosis, Engagement, Patient.
What interventions are being tested in trial NCT05310838?
The interventions under investigation include: Treatment As Usual (BEHAVIORAL), Behavioral Activation for First Episode Psychosis (BEHAVIORAL).
Who is sponsoring clinical trial NCT05310838?
This trial is sponsored by California State University, San Bernardino, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05310838 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for First Episode Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05310838's enrollment target sits among peer trials
58 7th of 8 higher than 2 of 8 other First Episode Psychosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other First Episode Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
RECRUITING · NA
-
Digital Strategies to Advance Help-Seeking - Aim 3
RECRUITING · NA
-
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
RECRUITING · NA
-
Digital Strategies to Advance Help-Seeking Aim 1 and 2
RECRUITING
-
Early-Phase Schizophrenia: Practice-based Research to Improve Outcomes
RECRUITING
-
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI